We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Leading drugmakers are urging the FDA to think bigger about its master protocol guidelines for clinical trials and expand beyond cancer trials. Read More
The Justice Department took back nearly $3 billion through judgments and settlements in fraud and false claims cases in fiscal year 2018 — with $2.5 billion of the recoveries involving the healthcare industry, including drugmakers, pharmacies and physicians. Read More
The investigation found breakdowns within the distributors’ anti-diversion strategies and serious failures to report suspicious drug orders by individual pharmacies. Read More
Of the task force members, Wyden noted, 15 are subject to reporting requirements under the CMS Open Payments system, a database that documents drug and devicemakers’ payments to physicians and teaching hospitals. Read More
“The nefarious tactics that drug companies use to influence state Medicaid programs’ drug coverage decisions are dishonest and disturbing,” said Booker. Read More
The generic drugmakers at the center of a multistate antitrust suit asked a Philadelphia federal court to impose a gag order on investigators after a Washington Post story published earlier this month revealed key details about the case. Read More
A federal jury on Tuesday convicted a former physician assistant of participating in a conspiracy to prescribe Insys’ potent fentanyl spray in exchange for kickbacks. Read More
Attorneys for the U.S. Public Interest Research Group and for two groups of independent pharmacists’ filed petitions asking Leon to hear their arguments against the merger. Read More